Expert Ratings For Allakos
Allakos (NASDAQ:ALLK) has observed the following analyst ratings within the last quarter:
Mid-Morning Market Update: Markets Edge Higher; CarMax Profit Tops Estimates
Following the market opening Wednesday, the Dow traded up 0.11% to 35,530.68 while the NASDAQ rose 0.02% to 15,344.33. The S&P also rose, gaining 0.13% to 4,655.40.
Allakos’ Shares Nosedive After Lirentelimab Studies Fail To Achieve Statistical Significance On Symptomatic Endpoints
Allakos Inc (NASDAQ: ALLK) reported data from ENIGMA 2 Phase 3 study of lirentelimab in eosinophilic gastritis (EG) or eosinophilic duodenitis (EoD) and KRYPTOS Phase 2/3 study of lirentelimab in eosinophilic esophagitis (EoE).
Cowen & Co. Downgrades Allakos to Market Perform
Cowen & Co. analyst Joseph Moore downgrades Allakos (NASDAQ:ALLK) from Outperform to Market Perform.
SVB Leerink Downgrades Allakos to Market Perform, Lowers Price Target to $17
SVB Leerink analyst Thomas Smith downgrades Allakos (NASDAQ:ALLK) from Outperform to Market Perform and lowers the price target from $150 to $17.
Barclays Maintains Underweight on Allakos, Lowers Price Target to $8
Barclays analyst Carter Gould maintains Allakos (NASDAQ:ALLK) with a Underweight and lowers the price target from $36 to $8.
B of A Securities Maintains Buy on Allakos, Raises Price Target to $155
B of A Securities analyst Jason Zemansky maintains Allakos (NASDAQ:ALLK) with a Buy and raises the price target from $145 to $155.
Allakos Sponsored Study Titled ‘A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis (ATLAS)’ Posted To ClinicalTrials.gov; Study Is Recruiting
https://clinicaltrials.gov/ct2/show/NCT05155085
Morgan Stanley Maintains Equal-Weight on Allakos, Lowers Price Target to $86
Morgan Stanley analyst Michael Ulz maintains Allakos (NASDAQ:ALLK) with a Equal-Weight and lowers the price target from $88 to $86.
Allakos Q3 EPS $(1.16) Misses $(1.12) Estimate
Allakos (NASDAQ:ALLK) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(1.12) by 3.57 percent. This is a 34.88 percent decrease over losses of $(0.86) per share from the same